Aprea Therapeutics (APRE)
Aprea Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
621K
Short interest
settlement 2026-10-15
2.2
Days to cover
-0.2 days vs prior
21.1%
Short share of volume
2026-11-02
2,584
Fails to deliver
settlement 2026-10-13
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in APRE is 621,151 shares, up 46,546 shares over the last month. Over the last 48 readings it ranged from 5,487 shares (14 August 2026) to 640,347 shares (31 March 2026). The latest reading sits at the top of that range. At the reported average volume of 279K shares a day that is 2.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/apre" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 621,151 | +22.1% | 278,538 | 2.23 |
| 2026-09-30 | 508,841 | -11.4% | 207,556 | 2.45 |
| 2026-09-15 | 574,605 | -6.8% | 177,428 | 3.24 |
| 2026-08-31 | 616,887 | +11142.7% | 893,115 | 1.00 |
| 2026-08-14 | 5,487 | -86.6% | 46,742 | 1.00 |
| 2026-07-31 | 41,083 | -32.2% | 47,642 | 1.00 |
| 2026-07-15 | 60,595 | -22.1% | 74,736 | 1.00 |
| 2026-06-30 | 77,797 | +22.5% | 100,138 | 1.00 |
| 2026-06-15 | 63,530 | -46.6% | 126,040 | 1.00 |
| 2026-05-29 | 119,012 | -19.4% | 148,030 | 1.00 |
| 2026-05-15 | 147,564 | +43.2% | 224,819 | 1.00 |
| 2026-04-30 | 103,019 | -6.3% | 264,571 | 1.00 |
| 2026-04-15 | 109,910 | -82.8% | 410,244 | 1.00 |
| 2026-03-31 | 640,347 | +500.4% | 832,163 | 1.00 |
| 2026-03-13 | 106,655 | -56.6% | 105,670 | 1.01 |
| 2026-02-27 | 245,983 | -3.5% | 637,902 | 1.00 |
| 2026-02-13 | 255,047 | -1.9% | 563,996 | 1.00 |
| 2026-01-30 | 260,110 | +623.6% | 11,506,003 | 1.00 |
| 2026-01-15 | 35,947 | +0.9% | 86,355 | 1.00 |
| 2025-12-31 | 35,625 | +3.0% | 53,836 | 1.00 |
| 2025-12-15 | 34,578 | -41.3% | 100,933 | 1.00 |
| 2025-11-28 | 58,925 | -6.9% | 35,046 | 1.68 |
| 2025-11-14 | 63,277 | -9.0% | 96,786 | 1.00 |
| 2025-10-31 | 69,543 | +39.5% | 184,290 | 1.00 |
| 2025-10-15 | 49,837 | -42.3% | 67,423 | 1.00 |
| 2025-09-30 | 86,411 | +1.6% | 42,471 | 2.03 |
| 2025-09-15 | 85,074 | +0.7% | 33,457 | 2.54 |
| 2025-08-29 | 84,496 | +42.4% | 38,642 | 2.19 |
| 2025-08-15 | 59,320 | +5.1% | 67,297 | 1.00 |
| 2025-07-31 | 56,425 | -10.7% | 53,635 | 1.05 |
| 2025-07-15 | 63,189 | -20.1% | 41,317 | 1.53 |
| 2025-06-30 | 79,127 | +8.5% | 78,556 | 1.01 |
| 2025-06-13 | 72,909 | -1.0% | 26,624 | 2.74 |
| 2025-05-30 | 73,646 | +24.8% | 35,007 | 2.10 |
| 2025-05-15 | 59,011 | -1.6% | 25,489 | 2.32 |
| 2025-04-30 | 59,980 | -0.6% | 19,555 | 3.07 |
| 2025-04-15 | 60,369 | +1.1% | 34,275 | 1.76 |
| 2025-03-31 | 59,744 | +7.4% | 20,966 | 2.85 |
| 2025-03-14 | 55,649 | +28.1% | 23,218 | 2.40 |
| 2025-02-28 | 43,458 | -6.2% | 29,920 | 1.45 |
| 2025-02-14 | 46,312 | +3.2% | 35,876 | 1.29 |
| 2025-01-31 | 44,890 | +270.9% | 27,095 | 1.66 |
| 2025-01-15 | 12,103 | +10.7% | 47,076 | 1.00 |
| 2024-12-31 | 10,932 | -14.3% | 22,670 | 1.00 |
| 2024-12-13 | 12,750 | +16.1% | 30,536 | 1.00 |
| 2024-11-29 | 10,983 | +15.5% | 9,387 | 1.17 |
| 2024-11-15 | 9,511 | -67.2% | 14,164 | 1.00 |
| 2024-10-31 | 28,953 | +90.8% | 43,364 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of APRE volume is 21.1%, down 48.5 points over the last five sessions. Over the last 30 readings it ranged from 14.3% (28 October 2026) to 72.9% (7 October 2026). The latest reading is 20.3 points below the 30-session average of 41.5%, on 56K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 12K | 56K | 21.1% | 0 |
| 2026-10-30 | 49K | 96K | 50.6% | 0 |
| 2026-10-29 | 13K | 81K | 15.7% | 313 |
| 2026-10-28 | 18K | 128K | 14.3% | 0 |
| 2026-10-27 | 30K | 93K | 32.6% | 58 |
| 2026-10-26 | 193K | 278K | 69.6% | 42,786 |
| 2026-10-23 | 25K | 37K | 66.4% | 700 |
| 2026-10-22 | 24K | 69K | 34.4% | 0 |
| 2026-10-21 | 10K | 47K | 21.4% | 0 |
| 2026-10-20 | 96K | 161K | 59.7% | 0 |
| 2026-10-19 | 22K | 52K | 43.5% | 0 |
| 2026-10-16 | 34K | 62K | 54.0% | 0 |
| 2026-10-15 | 16K | 44K | 36.5% | 100 |
| 2026-10-14 | 21K | 30K | 69.4% | 0 |
| 2026-10-13 | 30K | 75K | 39.5% | 0 |
| 2026-10-12 | 10K | 64K | 15.5% | 0 |
| 2026-10-09 | 25K | 43K | 58.7% | 500 |
| 2026-10-08 | 43K | 88K | 48.3% | 0 |
| 2026-10-07 | 78K | 107K | 72.9% | 0 |
| 2026-10-06 | 20K | 88K | 22.8% | 1 |
| 2026-10-05 | 70K | 167K | 41.9% | 0 |
| 2026-10-02 | 335K | 694K | 48.3% | 80,844 |
| 2026-10-01 | 359K | 569K | 63.0% | 35,281 |
| 2026-09-30 | 206K | 460K | 44.8% | 119 |
| 2026-09-29 | 144K | 464K | 31.1% | 0 |
| 2026-09-28 | 11K | 26K | 42.9% | 0 |
| 2026-09-25 | 11K | 30K | 38.2% | 0 |
| 2026-09-24 | 4K | 19K | 22.1% | 0 |
| 2026-09-23 | 87K | 180K | 48.2% | 0 |
| 2026-09-22 | 20K | 116K | 16.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in APRE is 2,584 shares, down 3,148 shares over the last settlement date. Over the last 30 readings it ranged from 8 shares (7 July 2026) to 27,121 shares (23 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 2,584 | $0.59 | $2K |
| 2026-10-02 | 5,732 | $0.72 | $4K |
| 2026-09-30 | 4,302 | $0.77 | $3K |
| 2026-09-24 | 509 | $0.78 | $397 |
| 2026-09-15 | 746 | $0.78 | $582 |
| 2026-09-09 | 21 | $0.84 | $18 |
| 2026-09-03 | 13 | $0.82 | $11 |
| 2026-09-02 | 9,908 | $0.84 | $8K |
| 2026-09-01 | 4,049 | $0.80 | $3K |
| 2026-08-27 | 22,375 | $0.98 | $22K |
| 2026-08-26 | 14,851 | $0.95 | $14K |
| 2026-08-25 | 2,983 | $0.81 | $2K |
| 2026-08-24 | 13 | $0.64 | $8 |
| 2026-08-21 | 13 | $0.63 | $8 |
| 2026-08-20 | 13 | $0.67 | $9 |
| 2026-08-13 | 30 | $0.68 | $20 |
| 2026-07-30 | 7,700 | $0.62 | $5K |
| 2026-07-29 | 13 | $0.63 | $8 |
| 2026-07-28 | 13 | $0.62 | $8 |
| 2026-07-27 | 13 | $0.64 | $8 |
| 2026-07-15 | 40 | $0.73 | $29 |
| 2026-07-13 | 175 | $0.75 | $131 |
| 2026-07-09 | 6,462 | $0.74 | $5K |
| 2026-07-07 | 8 | $0.75 | $6 |
| 2026-06-26 | 736 | $0.79 | $581 |
| 2026-06-24 | 84 | $0.83 | $70 |
| 2026-06-23 | 27,121 | $0.79 | $21K |
| 2026-06-22 | 69 | $0.72 | $50 |
| 2026-06-18 | 535 | $0.78 | $417 |
| 2026-06-17 | 4,430 | $0.73 | $3K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for APRE in the last 90 days. The most recent filings are listed below. Latest filing: Grissinger Michael (Director) on 2026-06-16.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Grissinger Michael | Director | Grant | 3K | $0.00 | $0 | 6K |
| 2026-06-16 | Gruia Gabriela | Director | Grant | 3K | $0.00 | $0 | 4K |
| 2026-06-16 | Peters Richard | Director | Grant | 3K | $0.00 | $0 | 6K |
| 2026-06-16 | HENNEMAN JOHN B III | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2026-06-16 | BIZZARI JEAN-PIERRE | Director | Grant | 3K | $0.00 | $0 | 4K |
| 2026-06-16 | Duey Marc | Director | Grant | 3K | $0.00 | $0 | 259K |
| 2026-06-16 | Pamukcu Rifat | Director | Grant | 3K | $0.00 | $0 | 9K |
| 2026-06-16 | Seizinger Bernd R. | Director | Grant | 3K | $0.00 | $0 | 49K |
| 2026-03-12 | Gilad Oren | President/CEO | Grant | 20K | $0.00 | $0 | 394K |
| 2026-03-12 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant | 10K | $0.00 | $0 | 44K |
| 2026-01-30 | Gilad Oren | President/CEO | Buy | 28K | $0.89 | $25K | 374K |
| 2026-01-30 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 6K | $0.89 | $5K | 33K |
| 2025-12-10 | Duey Marc | Director | Buy | 21K | $1.17 | $25K | 256K |
| 2025-12-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5K | $1.17 | $6K | 28K |
| 2025-06-05 | BIZZARI JEAN-PIERRE | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2025-06-05 | Duey Marc | Director | Grant | 1K | $0.00 | $0 | 235K |
| 2025-06-05 | Grissinger Michael | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2025-06-05 | Gruia Gabriela | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2025-06-05 | HENNEMAN JOHN B III | Director | Grant | 1K | $0.00 | $0 | 10K |
| 2025-06-05 | Pamukcu Rifat | Director | Grant | 1K | $0.00 | $0 | 5K |
| 2025-06-05 | Peters Richard | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2025-06-05 | Seizinger Bernd R. | Director | Grant | 1K | $0.00 | $0 | 46K |
| 2025-04-03 | Gilad Oren | President/CEO | Buy | 3K | $1.87 | $6K | 343K |
| 2025-04-03 | Gilad Oren | President/CEO | Buy | 2K | $1.80 | $4K | 346K |
| 2025-03-27 | Gilad Oren | President/CEO | Grant | 7K | $0.00 | $0 | 340K |
| 2025-03-27 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant | 3K | $0.00 | $0 | 23K |
| 2024-10-23 | Gilad Oren | President/CEO | Buy | 500 | $3.92 | $2K | 333K |
| 2024-10-18 | Duey Marc | Director | Sell | 6K | $4.58 | $30K | 234K |
| 2024-10-16 | Duey Marc | Director | Buy | 30K | $4.39 | $132K | 240K |
| 2024-10-15 | Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725 | 333K |
| 2024-10-14 | Gilad Oren | President/CEO | Buy | 1K | $2.59 | $3K | 333K |
| 2024-10-14 | Duey Marc | Director | Buy | 190 | $2.58 | $490 | 210K |
| 2024-10-11 | Seizinger Bernd R. | Director | Buy | 10K | $2.68 | $27K | 45K |
| 2024-10-11 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123 | 19K |
| 2024-10-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1K | 19K |
| 2024-10-10 | Gilad Oren | President/CEO | Buy | 150 | $2.54 | $381 | 332K |
| 2024-06-20 | Duey Marc | Director | Grant | 1K | $0.00 | $0 | 210K |
| 2024-06-20 | Grissinger Michael | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2024-06-20 | HENNEMAN JOHN B III | Director | Grant | 1K | $0.00 | $0 | 9K |
| 2024-06-20 | Peters Richard | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2024-06-20 | Pamukcu Rifat | Director | Grant | 1K | $0.00 | $0 | 4K |
| 2024-06-20 | Seizinger Bernd R. | Director | Grant | 1K | $0.00 | $0 | 35K |
| 2024-05-01 | Mirza Nadeem Q. | Chief Medical Officer | Grant | 7K | $0.00 | $0 | 7K |
| 2024-03-28 | Gilad Oren | President, CEO | Grant | 7K | $0.00 | $0 | 331K |
| 2024-03-28 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant | 3K | $0.00 | $0 | 19K |
| 2024-03-13 | Gilad Oren | President, CEO | Buy | 2K | $7.29 | $15K | 325K |
| 2024-03-13 | HENNEMAN JOHN B III | Director | Buy | 7K | $7.29 | $50K | 8K |
| 2024-03-13 | Seizinger Bernd R. | Director | Buy | 7K | $7.29 | $50K | 34K |
| 2024-03-13 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1K | $7.29 | $7K | 16K |
| 2023-08-23 | Seizinger Bernd R. | Director | Grant | 500 | $0.00 | $0 | 27K |
| 2023-08-23 | Duey Marc | Director | Grant | 500 | $0.00 | $0 | 209K |
| 2023-08-23 | Peters Richard | Director | Grant | 500 | $0.00 | $0 | 1K |
| 2023-08-23 | HENNEMAN JOHN B III | Director | Grant | 500 | $0.00 | $0 | 1K |
| 2023-08-23 | Grissinger Michael | Director | Grant | 500 | $0.00 | $0 | 799 |
| 2023-08-23 | Pamukcu Rifat | Director | Grant | 500 | $0.00 | $0 | 3K |
| 2023-06-07 | Seizinger Bernd R. | Director | Buy | 6K | $3.68 | $22K | 26K |
| 2023-06-06 | Seizinger Bernd R. | Director | Buy | 4K | $3.63 | $15K | 20K |
| 2023-03-09 | Gilad Oren | President, CEO | Grant | 4K | $0.00 | $0 | 323K |
| 2023-02-27 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant | 1K | $5.25 | $5K | 14K |
| 2023-01-30 | Hamill John P. | SrVP/CFO/Prin. Fin&Acctg. Off | Grant | 270K | $0.00 | $0 | 270K |
| 2022-08-23 | Duey Marc | Director | Conversion | 4.0M | $0.00 | $0 | 4.2M |
| 2022-08-23 | Duey Marc | Director | Conversion | 12K | $0.00 | $0 | 602 |
| 2022-08-23 | Pamukcu Rifat | Director | Conversion | 272K | $0.00 | $0 | 14K |
| 2022-08-23 | Pamukcu Rifat | Director | Conversion | 49K | $0.00 | $0 | 57K |
| 2022-08-23 | Gilad Oren | President, CEO | Conversion | 6.0M | $0.00 | $0 | 6.4M |
| 2022-07-28 | Coiante Scott M | SVP, Chief Financial Officer | Grant | 61K | $0.00 | $0 | 145K |
| 2022-07-28 | Duey Marc | Director | Grant | 6K | $0.00 | $0 | 158K |
| 2022-07-28 | Gilad Oren | President, CEO | Grant | 101K | $0.00 | $0 | 330K |
| 2022-07-28 | Grissinger Michael | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2022-07-28 | HENNEMAN JOHN B III | Director | Grant | 6K | $0.00 | $0 | 16K |
| 2022-07-28 | Korbel Gregory Alan | SVP, Chief Operating Officer | Grant | 24K | $0.00 | $0 | 46K |
| 2022-07-28 | Pamukcu Rifat | Director | Grant | 6K | $0.00 | $0 | 8K |
| 2022-07-28 | Peters Richard | Director | Grant | 6K | $0.00 | $0 | 11K |
| 2022-07-28 | SCHADE CHRISTIAN S | Director | Grant | 32K | $0.00 | $0 | 259K |
| 2022-07-28 | Seizinger Bernd R. | Director | Grant | 6K | $0.00 | $0 | 325K |
| 2022-06-03 | Attar Eyal C. | SVP, Chief Medical Officer | Tax withholding | 33K | $0.81 | $26K | 57K |
| 2022-06-03 | Korbel Gregory Alan | SVP, Chief Operating Officer | Tax withholding | 8K | $0.81 | $7K | 21K |
| 2022-06-03 | Coiante Scott M | SVP, Chief Financial Officer | Tax withholding | 35K | $0.81 | $29K | 84K |
| 2022-06-03 | SCHADE CHRISTIAN S | Chairman & CEO | Tax withholding | 66K | $0.81 | $53K | 227K |
| 2022-05-18 | SCHADE CHRISTIAN S | Chairman & CEO | Buy | 38K | $0.64 | $24K | 293K |
| 2022-05-18 | Seizinger Bernd R. | Director | Buy | 50K | $0.71 | $36K | 319K |
| 2022-03-10 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Grant | 25K | $0.00 | $0 | 44K |
| 2022-03-10 | Attar Eyal C. | SVP, Chief Medical Officer | Grant | 43K | $0.00 | $0 | 90K |
| 2022-03-10 | Coiante Scott M | SVP, Chief Financial Officer | Grant | 43K | $0.00 | $0 | 120K |
| 2022-03-10 | Korbel Gregory Alan | SVP, Chief Business Officer | Grant | 16K | $0.00 | $0 | 32K |
| 2022-03-10 | Korbel Gregory Alan | SVP, Chief Business Officer | Tax withholding | 2K | $1.82 | $4K | 30K |
| 2022-03-10 | SCHADE CHRISTIAN S | Chairman & CEO | Grant | 100K | $0.00 | $0 | 255K |
| 2022-02-28 | Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36K | $1.73 | $62K | 47K |
| 2022-02-25 | Coiante Scott M | SVP, Chief Financial Officer | Tax withholding | 15K | $1.74 | $26K | 77K |
| 2022-02-25 | Korbel Gregory Alan | SVP, Chief Business Officer | Tax withholding | 1K | $1.74 | $2K | 16K |
| 2022-02-25 | SCHADE CHRISTIAN S | Chairman & CEO | Tax withholding | 22K | $1.74 | $38K | 155K |
| 2021-12-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 28K | $3.96 | $109K | 17K |
| 2021-12-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Exercise or conversion | 28K | $0.92 | $25K | 45K |
| 2021-11-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Exercise or conversion | 28K | $0.92 | $25K | 45K |
| 2021-11-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 28K | $5.00 | $138K | 17K |
| 2021-10-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Exercise or conversion | 28K | $0.92 | $25K | 45K |
| 2021-10-01 | Korbel Gregory Alan | SVP, Chief Business Officer | Sell | 28K | $4.89 | $134K | 17K |
| 2021-10-01 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Exercise or conversion | 50K | $0.92 | $46K | 69K |
| 2021-10-01 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Sell | 50K | $4.89 | $245K | 19K |
| 2021-09-20 | Abrahmsen Lars B. | SVP, Chief Scientific Officer | Exercise or conversion | 25K | $0.92 | $23K | 44K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON17 holders report 5% or more of APRE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Soleus Private Equity Fund III, L.P. at 10.0% of the class (1,271,080 shares), filed 2026-04-01 for an event on 2026-04-01.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 1 | LYTTON LAURENCE Windividual | 391K | 3.2% | 2026-06-30 |
| 2026-05-15 | 13G | Ryan Wilderparent holding company, individual | 22.7M | 9.9% | 2026-03-31 |
| 2026-05-15 | 13G | Vestal Point Capital, LPinvestment adviser, partnership | 22.7M | 9.9% | 2026-03-31 |
| 2026-04-27 | 13G/Ano. 4 | Orin Hirschmanparent holding company, individual | 1.2M | 9.9% | 2026-03-31 |
| 2026-04-27 | 13G/Ano. 4 | AIGH Capital Management LLCinvestment adviser, other entity | 1.2M | 9.9% | 2026-03-31 |
| 2026-04-07 | 13G | Squadron Master Fund LPpartnership | 1.3M | 9.9% | 2026-03-30 |
| 2026-04-07 | 13G | Squadron Capital Management LLCinvestment adviser, parent holding company | 1.3M | 9.9% | 2026-03-30 |
| 2026-04-07 | 13G | William Blankindividual, parent holding company | 1.3M | 9.9% | 2026-03-30 |
| 2026-04-07 | 13G | Matthew Sesterhennparent holding company, individual | 1.3M | 9.9% | 2026-03-30 |
| 2026-04-01 | 13G | Soleus Private Equity Fund III, L.P.partnership | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus Private Equity GP III, LLCother entity | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus PE GP III, LLCother entity | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus Capital Master Fund, L.P.non-US institution | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus Capital, LLCother entity | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus Capital Group, LLCother entity | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus Capital Management, L.P.partnership | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Soleus GP, LLCother entity | 1.3M | 10.0% | 2026-04-01 |
| 2026-04-01 | 13G | Guy Levyindividual | 1.3M | 10.0% | 2026-04-01 |
| 2026-02-13 | 13G/Ano. 1 | Nantahala Capital Management, LLCinvestment adviser | 412K | 4.5% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Wilmot B. Harkeyparent holding company | 412K | 4.5% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Daniel Mackparent holding company | 412K | 4.5% | 2025-12-31 |
| 2025-11-12 | 13G/Ano. 4 | Sio Capital Management, LLCinvestment adviser | 112K | 1.9% | 2025-09-30 |
13F holders
Tracked managers holding APRE at their latest 13F. JSON2 of the 30 tracked managers held APRE at their latest 13F, $132K in total at quarter-end prices. Renaissance Technologies is the largest at $85K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 106K | $85K | 0.00% | +81K |
| Citadel Advisors | 2026-06-30 | 59K | $47K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Aprea Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Aprea Therapeutics (APRE), SEC CIK 1781983, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-16.JSON and CSV
- Company record
- EDGAR filing index for CIK 1781983Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of APRE is sold short?
621,151 shares were held short at the 2026-10-15 settlement, 2.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is APRE's daily short volume?
On 2026-11-02, 11,733 of the 55,516 APRE shares reported to FINRA were sold short, 21.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does APRE have fails to deliver?
The SEC's latest file shows 2,584 APRE shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are APRE insiders buying or selling?
No open-market insider trades were reported for APRE in the last 90 days. The most recent filings are listed below. Latest filing: Grissinger Michael (Director) on 2026-06-16.
Who owns 5% or more of APRE?
17 holders report 5% or more of APRE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Soleus Private Equity Fund III, L.P. at 10.0% of the class (1,271,080 shares), filed 2026-04-01 for an event on 2026-04-01.
Which tracked 13F managers own APRE?
2 of the 30 tracked 13F managers held APRE shares at their latest filing, $132K in all. The largest: Renaissance Technologies (106K shares, $85K), Ken Griffin's Citadel Advisors (59K shares, $47K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.